# TolerRx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tolerrx

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.tolerx.com
- Total disclosed funding: $118M
- Latest round: Series D (Aug 14, 2006)
- Investors on record: 13

## About

TolerRx Inc. is a biotechnology company focused on developing innovative therapies for autoimmune diseases, leveraging advanced immunological research to enhance patient care.Founded in 2000, TolerRx Inc. is based in Cambridge, US, and specializes in treatments for autoimmune disorders. The company has successfully completed 5 deals, with its most recent financing round occurring in December 2010, where it raised USD 1.5 mn. The firm has a notable history in securing funding to support its research and development efforts in immunotherapy.TolerRx.com primarily operates as a domain sales platform, focusing on providing premium domain names to individuals and businesses looking to establish an online presence. The core service offered is the sale of the domain name Tolerx.com, which is currently priced at USD 5,295, with an option for a 12-month payment plan at USD 441.25 per month. This service is targeted towards entrepreneurs, startups, and established companies across various industries that recognize the importance of a strong digital identity. By facilitating the acquisition of desirable domain names, Tolerx.com addresses the need for memorable and relevant web addresses that enhance branding and visibility in the competitive online market. The platform serves clients primarily in North America and Europe, allowing access to a global customer base that seeks to enhance its digital footprint.The revenue model of Tolerx.com is centered around direct sales of domain names, with a structured pricing strategy that includes both outright purchases and financing options. Clients engage in transactions by either paying the full price for the domain or opting for a monthly installment plan, which allows for greater accessibility in acquiring premium domain names without a significant upfront investment. Each domain sold is accompanied by a 30-day money-back guarantee, ensuring customer satisfaction and fostering trust in the transaction process. This model is typical in the domain registration industry, where businesses often seek to secure unique web addresses that align with their branding strategies. Through this approach, Tolerx.com generates revenue from individual customers while also catering to businesses that require specific domain names for their online operations.TolerRx Inc. has plans to leverage the recent financing of USD 1.5 mn raised in December 2010 to enhance its product offerings and expand its market reach. The company is focusing on the development of new immunotherapy products aimed at combating autoimmune diseases, with potential launches anticipated over the next few years. Additionally, TolerRx Inc. is exploring opportunities to enter new geographic markets in Europe and Asia by 2025, aiming to broaden its customer base and increase accessibility to innovative treatments.

## Funding rounds

- Series D, Aug 14, 2006, $35M — HealthCare Ventures, Mesirow Financial, RHO, Sprout Group, Skyline Ventures, Artal Services, O-Bank, Swiss Re Ltd, FrontPoint Partners, Bear Stearns Health Innoventures, QVT funds
- Series D, Mar 28, 2005, $31M — HealthCare Ventures, RHO, Skyline Ventures, Daiwa Corporate Investment, Bear Stearns Health Innoventures, Vertex Holdings
- Series C, Jan 3, 2003, $35M — HealthCare Ventures, RHO, Vertex Holdings
- Series B, Oct 23, 2001, $17M — HealthCare Ventures, RHO, Skyline Ventures, Vertex Holdings

## Investors

- HealthCare Ventures — Series B, Series C, Series D
- RHO (https://capitalatlas.ai/funds/rho) — Series B, Series C, Series D
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series B, Series D
- Vertex Holdings (https://capitalatlas.ai/funds/vertex-holdings) — Series B, Series C, Series D
- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series D
- Bear Stearns Health Innoventures (https://capitalatlas.ai/funds/bear-stearns-health-innoventures) — Series D
- Mesirow Financial (https://capitalatlas.ai/funds/mesirow-financial) — Series D
- Sprout Group (https://capitalatlas.ai/funds/sprout-group) — Series D
- Artal Services — Series D
- O-Bank (https://capitalatlas.ai/funds/o-bank) — Series D
- Swiss Re Ltd — Series D
- FrontPoint Partners — Series D
- QVT funds — Series D